Diffusion Pharmaceuticals Inc. (NasdaqCM: DFFN) Loss Submission Form

Kuznicki Law is investigating the proposed merger of Diffusion Pharmaceuticals Inc. (the “Company”) (NasdaqCM: DFFN) with EIP Pharma Inc. pursuant to which Diffusion shareholders will end up owning 22.75% of the total number of outstanding shares of the combined company, subject to adjustment. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.